Gland Pharma Limited (BOM: 543245)

Market Cap	291.99B
Revenue (ttm)	58.90B
Net Income (ttm)	6.92B
Shares Out	n/a
EPS (ttm)	41.98
PE Ratio	42.22
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Aug 16, 2024

Volume	1,522
Open	1,755.05
Previous Close	1,763.90
Day's Range	1,750.00 - 1,790.70
52-Week Range	1,590.00 - 2,220.95
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 3, 2025

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,217
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In 2023, Gland Pharma's revenue was 56.65 billion, an increase of 56.29% compared to the previous year's 36.25 billion. Earnings were 7.72 billion, a decrease of -1.10%.